Page 8 - Cipla

World in turmoil, domestic pharma firms target India for healthy growth

Share of India revenue in home-grown firms' consolidated turnover rising over the years

Cipla Q2 PAT up 11% PAT to Rs 789 cr on strong Covid-adjusted growth rate

The company is de-risking key product Abraxane in case the Goa plant FDA issue is not cleared immediately

Fag-end buying lifts Sensex 114 pts, Nifty above 18,100; Metal index up 4%

CLOSING BELL: A late rally on Dalal Street helped the benchmark indices end a lacklustre trading session on a positive note. Metals, select financial shares led the pullback.

Cipla Q2 net profit up 12% at Rs 797 crore, revenue rises to Rs 5,829 crore

Drug major Cipla on Friday said its consolidated net profit increased 12 per cent to Rs 797 crore for the second quarter ended September 30. The Mumbai-based drug maker had reported a consolidated net profit of Rs 709 crore in the July-September period of the previous fiscal. Its total revenue from operations rose to Rs 5,829 crore for the September quarter from Rs 5,520 crore in the year-ago period, Cipla said in a regulatory filing. In respect of the transfer of India-based US business undertaking, the board decided not to proceed with the proposed transfer, considering various factors, including the current operating environment, it added. Shares of the company were trading 0.5 per cent up at Rs 1,154.10 apiece on the BSE.

Pharma shares may turnaound soon; Cipla, Sun Pharma, Granules can gain 20%

What do expect from pharma stocks over the next few weeks? Here's what technical charts suggest.

Dr Reddy's, Cipla, and Aurobindo units recall products in US market

Leading drug firms Dr Reddy's Laboratories, Cipla and Aurobindo Pharma are recalling different products in the US market for various issues, according to the US Food and Drug Administration. As per the enforcement report by the US Food and Drug Administration (USFDA), the US-based unit of Dr Reddy's Laboratories is recalling 2,838 ampules of vitamin K deficiency treatment drug Phytonadione Injectable Emulsion. According to the USFDA, Dr Reddy's Laboratories is recalling the affected lot due to "failed stability specifications". "Out of specification results reported at 12-month stability testing for aluminum content," it stated. Dr Reddy's initiated the Class III voluntary recall on September 14 this year. As per USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences". USFDA further said the US-based arm of domestic drug major Cipla is recalling 9,041 cartons of Arformoterol ..

India facilities of Cipla, Dr Reddy's Labs, join Global Lighthouse Network

The World Economic Forum on Tuesday announced the addition of 11 factories and industrial sites, including three from India, to its Global Lighthouse Network. From India, the additions are pharma major Cipla's Indore facility, Dr Reddy's Laboratories' Hyderabad facility and the Mondelez facility in Sri City. The Global Lighthouse Network is a community of over 100 manufacturers that are showing leadership in applying Fourth Industrial Revolution technologies such as artificial intelligence, 3D-printing and big data analytics. The WEF further said four lighthouse members with outstanding environmental footprint reductions have been given an additional designation of Sustainability Lighthouses. These four include Unilever's Dapada facility in India. The WEF said that amid warnings of a global recession, energy price hikes and disrupted supply chains, the lighthouse factories offer business leaders and policymakers examples of how the manufacturing sector can stay competitive and ...

Nifty Pharma index surpasses 200-DMA; Cipla, Granules can soar up to 15%

The Pharma benchmark has outperformed the overall market in recent trading sessions; sustenance above 200-DMA is likely to trigger further gains for it

Nifty Pharma outshines benchmarks, up 2%; Cipla, Sun Pharma hit 52-wk highs

Shares of Glenmark Pharma, Granules India, Divi's Laboratories, Torrent Pharma, Lupin and Aurobindo Pharma, surged in the range of 2 per cent to 6 per cent in Monday's intra-day trade

Indian generic formulation-makers level of capex declining: Candle Partners

Candle Partners study shows that from the peak of 30% of gross block in FY16, the capex is down to 9-10% of gross block

Growth forecast in US market set to drive gains for Cipla stock

Street remains bullish on India prospects, regulatory headwinds for Goa site continue

Nifty Pharma index sees biggest jump in four months, shows data

The Nifty Pharma index finished at 12,750, up 3.1 per cent - most since May 20 and third biggest single-day gain of the year

NLEM 2022: Analysts see no major impact pharma companies' growth

The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM include anti-infectives, anti-diabetics, anesthetics, etc

Fight against Covid-19: Here is a list of vaccines approved in India

Besides Bharat Biotech's nasal vaccine, India has 13 vaccines to fight against Covid-19. Two have been approved for manufacturing, while 11 have been approved for emergency use

Sensex slides 861 pts, Nifty holds 17,300; RIL slips 1% post 45th AGM

CLOSING BELL: Mukesh Ambani laid out succession plan with Akash Ambani championing telecom, Isha Ambani controlling Retail, and Anant Ambani joining new-energy vertical

The pink of health: Trade generics now key growth driver for Cipla

Vertical witnesses 25% CAGR in 5 yrs

Stocks to Watch: Cipla, NTPC, Adani group, SBI Cards, Hind Zinc, Nxtdigital

Stocks to Watch: ICICI Securities, Axis Capital and Citigroup Global Markets are among the 5 investment bankers selected to manage the sale of the government's 29.53% residual stake in Hindustan Zinc

India at 75: These pre-independence companies thrived in independent India

These companies that operated under the constraints of British rule before 1947 helped India become self-sufficient in various sectors after independence

Cipla betting big on digitisation and emerging segments like mRNA

Drug major Cipla is betting big on digitisation and emerging segments like biosimilars and mRNA aided medications to drive its next phase of growth. The Mumbai-based drug maker is also bullish on maximising value opportunity in the complex generics in the US market. It is also looking to scale up its US core formulations sales on the back of respiratory and peptide franchises while monitoring upcoming complex product launches in the second half of the current fiscal. "Digitalisation in healthcare found its rightful place during the pandemic, and there is a need to expand and support the essential backup services to enable digital healthcare to function efficiently in all primary and secondary healthcare centres," Cipla Executive Vice-Chairperson Samina Hamied said in the company's Annual Report for 2021-22. The drug firm has embarked on the digital transformation of the value chain across functions, including finance, R&D, manufacturing, supply chain, HR, customer outreach and ...

Stocks to Watch: YES Bank, Cipla, Bank of Baroda, Zomato, HDFC, ITC, NTPC

Stocks to Watch today: ITC, UPL, Zomato, Arvind, Bajaj Consumer Care, among others will release their Q1 earnings today.